Quarterly report · Q2
4572.TEDINET S100RGZ5
Period2023-01-01 → 2023-06-30
Filed2023-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥501m | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥840m | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | −¥864m | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | −¥312m | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | −¥868m | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥306m | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥869m | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥349m | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥886m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥359m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥886m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | −¥359m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥4.6bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥5.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥453m | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥625m | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.1bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.4bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.7bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.8bn | at 2021-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥939m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥708m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥585m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥126m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥57m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥367m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥166m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-53.81 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.46 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26.53 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.25 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥1.0bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥501m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥501m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥169m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥286m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥286m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥547m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥553m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥553m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥235m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 424
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in unearned revenue ope cf | Prior1YTDDuration | -137469000 | JPY |
| Increase decrease in unearned revenue ope cf | CurrentYTDDuration | － | JPY |
| Other net ope cf | Prior1YTDDuration | 1732000 | JPY |
| Other net ope cf | CurrentYTDDuration | 41922000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 594696000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -918919000 | JPY |
| Interest income received ope cf | Prior1YTDDuration | 57000 | JPY |
| Interest income received ope cf | CurrentYTDDuration | 84000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -2954000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -1650000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -8364000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -18058000 | JPY |
| Other net ope cf subtotal | Prior1YTDDuration | 1906000 | JPY |
| Other net ope cf subtotal | CurrentYTDDuration | － | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 585341000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -938544000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -57614000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -6854000 | JPY |
| Other net inv cf | Prior1YTDDuration | 305000 | JPY |
| Other net inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -57309000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -6854000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -120012000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -59994000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -14014000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -14014000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | 300374000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | 1296166000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 166348000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 1222158000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 172483000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 28818000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 866864000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 305577000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3817834000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3379048000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 4684699000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 3684625000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 745905000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 959587000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 553498000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 286045000 | JPY |
| Revenues from external customers | Prior1YTDDuration | 839543000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 553498000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | 286045000 | JPY |
| Net sales | Prior1YTDDuration | 839543000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 235138000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |